Abstract
The protease, human kallikrein-related peptidase 6 (hK6) is derived from activated macrophages in the central nervous system (CNS) and may contribute to pathology observed in multiple sclerosis (MS). In the present study, we compared serum and cerebrospinal fluid (CSF) protein concentrations of human kallikrein-related peptidase 6 derived from neurological controls and patients diagnosed with advanced multiple sclerotic disease. Mean serum levels of human kallikrein-related peptidase 6 were similar in neurological controls and patients diagnosed with relapsing-remitting (RR), secondary progressive (SP) and primary progressive (PP) multiple sclerosis with mean levels ranging from 3.5 to 3.75 ng/ml. Patients diagnosed with advanced multiple sclerosis showed mean CSF levels (29 ng/ml) that were significantly higher than neurological controls (25.5 ng/ml). Determining CSF concentrations of human kallikrein-related peptidase 6 may therefore have diagnostic value in MS.
Keywords: hK6, serum, CSF, RRMS, SPMS, PPMS, human kallikrein-related peptidase 6, central nervous system, cerebrospinal fluid, protease, inflammatory lesions, encephalomyelitis, ELISA, Tetramethylbenzidine, Alzheimer's disease, EDSS
Current Drug Discovery Technologies
Title: Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis
Volume: 7 Issue: 2
Author(s): Andrea L.O. Hebb, Virender Bhan, Alexander D. Wishart, Craig S. Moore and George S. Robertson
Affiliation:
Keywords: hK6, serum, CSF, RRMS, SPMS, PPMS, human kallikrein-related peptidase 6, central nervous system, cerebrospinal fluid, protease, inflammatory lesions, encephalomyelitis, ELISA, Tetramethylbenzidine, Alzheimer's disease, EDSS
Abstract: The protease, human kallikrein-related peptidase 6 (hK6) is derived from activated macrophages in the central nervous system (CNS) and may contribute to pathology observed in multiple sclerosis (MS). In the present study, we compared serum and cerebrospinal fluid (CSF) protein concentrations of human kallikrein-related peptidase 6 derived from neurological controls and patients diagnosed with advanced multiple sclerotic disease. Mean serum levels of human kallikrein-related peptidase 6 were similar in neurological controls and patients diagnosed with relapsing-remitting (RR), secondary progressive (SP) and primary progressive (PP) multiple sclerosis with mean levels ranging from 3.5 to 3.75 ng/ml. Patients diagnosed with advanced multiple sclerosis showed mean CSF levels (29 ng/ml) that were significantly higher than neurological controls (25.5 ng/ml). Determining CSF concentrations of human kallikrein-related peptidase 6 may therefore have diagnostic value in MS.
Export Options
About this article
Cite this article as:
L.O. Hebb Andrea, Bhan Virender, D. Wishart Alexander, S. Moore Craig and S. Robertson George, Human Kallikrein 6 Cerebrospinal Levels are Elevated in Multiple Sclerosis, Current Drug Discovery Technologies 2010; 7 (2) . https://dx.doi.org/10.2174/157016310793180611
DOI https://dx.doi.org/10.2174/157016310793180611 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Redox Regulation and the Autistic Spectrum: Role of Tryptophan Catabolites, Immuno-inflammation, Autoimmunity and the Amygdala
Current Neuropharmacology Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Current Drug Targets Subject Index To Volume-3
Letters in Drug Design & Discovery Adenosine A1 Receptors in the Central Nervous System: Their Functions in Health and Disease, and Possible Elucidation by PET Imaging
Current Medicinal Chemistry Macrophage Heterogeneity: Relevance and Functional Implications in Atherosclerosis
Current Vascular Pharmacology From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research CC Chemokine Receptor Small Molecule Antagonists in the Treatment of Rheumatoid Arthritis and Other Diseases: A Current View
Current Topics in Medicinal Chemistry Are B Cells a Potential Target for Therapeutic Intervention in the Classical T Cell-Mediated Autoimmune Disease Type 1 Diabetes?
Inflammation & Allergy - Drug Targets (Discontinued) Immunomodulatory Properties of Farnesoids: The New Steroids?
Current Medicinal Chemistry Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design A Comprehensive Review on Chrysin: Emphasis on Molecular Targets, Pharmacological Actions and Bio-pharmaceutical Aspects
Current Drug Targets The Role of Uric Acid and Methyl Derivatives in the Prevention of Age-Related Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Apoptotic Cell Clearance and Autoimmune Disorder
Current Medicinal Chemistry Neuroprotective Properties of Peroxisome Proliferator-Activated Receptor Alpha (PPARα) and its Lipid Ligands
Current Medicinal Chemistry Neuroimaging of Central Sensitivity Syndromes: Key Insights from the Scientific Literature
Current Rheumatology Reviews Challenges in the Design of Clinically Useful Brain-targeted Drug Nanocarriers
Current Medicinal Chemistry Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy